Back to top
more

NanoString Technologies, Inc. (NSTG)

(Delayed Data from NSDQ)

$27.96 USD

27.96
266,767

+0.86 (3.17%)

Updated May 3, 2019 04:00 PM ET

After-Market: $27.94 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Quipt Home Medical Corp. (QIPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 66.67% and 3.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 7.22% and 4.13%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

NanoString (NSTG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for NanoString (NSTG) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline

by Zacks Equity Research

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NanoString Technologies (NSTG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NanoString (NSTG) Grows in Translational Research With CRO Deals

by Zacks Equity Research

According to NanoString (NSTG), SMI's unique ability to interrogate both RNA and proteins at ultra-high plex with subcellular resolution has made it a one-of-a-kind tool.

NanoString (NSTG) Advances in Xenotransplantation With New Study

by Zacks Equity Research

NanoString's (NSTG) nCounter Analysis System facilitates bulk tissue transcriptome profiling, revealing the intricacies of the immune response through the nCounter Human Organ Transplant Panel.

Compared to Estimates, NanoString (NSTG) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for NanoString (NSTG) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

NanoString Technologies (NSTG) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

NanoString (NSTG) delivered earnings and revenue surprises of -22.22% and 8.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

NanoString Technologies (NSTG) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

NanoString (NSTG) delivered earnings and revenue surprises of -55.74% and 3.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NanoString Technologies (NSTG) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

NanoString (NSTG) delivered earnings and revenue surprises of -71.74% and 16.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Misses Q3 Earnings Estimates

by Zacks Equity Research

Stryker (SYK) delivered earnings and revenue surprises of -5.36% and 0.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think NanoString (NSTG) Could Surge 116%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at an 116.4% upside potential for NanoString (NSTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

NanoString Technologies (NSTG) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

NanoString (NSTG) delivered earnings and revenue surprises of -37.10% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: NanoString Technologies (NSTG) Q2 Earnings Expected to Decline

by Zacks Equity Research

NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts See a 172% Upside in NanoString (NSTG): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 171.7% upside potential for NanoString (NSTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

NanoString (NSTG) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

NanoString (NSTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet (ZBH) might have struggled to maintain the recovery trend in the first half of Q1 with severe-than-expected staffing shortages and supply issues leading to procedural deferrals.

Bio-Rad (BIO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) first-quarter top line.

Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results reflect strong segmental performance.

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Based on a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Diagnostics and GYN Surgical businesses is likely to have contributed to Hologic's (HOLX) fiscal second-quarter revenues.

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

by Zacks Equity Research

Given an innovative pipeline, expansion into faster growth markets, globalization efforts and enhanced digital capabilities, Boston Scientific (BSX) is well-positioned to register strong first quarter of 2022 results.

Abbott's (ABT) Q1 Earnings and Revenues Exceed Estimates

by Zacks Equity Research

Within Adult Nutrition, Abbott (ABT) gains from the strong performance of Ensure and Glucerna brands in Q1.

Edwards Lifesciences (EW) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) first-quarter performance.